ストックスクリーナーアプリを入手
15.30
1.92%
-0.29
前日終値:
$15.59
開ける：
$15.59
24時間の取引高:
26,293
Relative Volume:
0.05
時価総額：
$621.01M
収益：
-
当期純損益:
$-168.05M
株価収益率:
-2.9825
EPS:
-5.13
ネットキャッシュフロー:
$-146.15M
1週間 パフォーマンス:
+0.53%
1か月 パフォーマンス:
+11.36%
6か月 パフォーマンス:
+34.36%
1年 パフォーマンス:
-70.88%
1日の値動き範囲:
$15.26
$15.59
1週間の範囲:
$15.22
$16.07
52週間の値動き範囲:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
名前
Keros Therapeutics Inc
セクター
電話
617-314-6297
住所
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
KROS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
15.29 | 633.19M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.42 | 101.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.25B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.20 | 60.77B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
758.72 | 45.95B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.85 | 37.61B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-01-21 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-12-16 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-12-16 | 繰り返されました | Oppenheimer | Outperform |
| 2024-12-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-12 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-12-12 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-12-12 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | 開始されました | Jefferies | Buy |
| 2024-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-23 | 開始されました | Guggenheim | Buy |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-02-21 | 開始されました | William Blair | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-07-31 | 開始されました | Wedbush | Outperform |
| 2023-07-26 | 開始されました | BofA Securities | Buy |
| 2023-02-14 | 開始されました | Cowen | Outperform |
| 2022-10-18 | 開始されました | Truist | Buy |
| 2022-07-26 | 開始されました | BTIG Research | Buy |
| 2020-12-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-04 | 開始されました | Jefferies | Buy |
| 2020-05-04 | 開始されました | Piper Sandler | Overweight |
| 2020-05-04 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Keros Therapeutics Inc (KROS) 最新ニュース
Keros Therapeutics reports positive data for DMD drug candidate - Investing.com
Keros Therapeutics Presents Promising Phase 1 Trial Data - TipRanks
Keros Therapeutics Presents Additional Clinical Data from - GlobeNewswire
Sustained Bone Density Gains: Keros' KER-065 Shows Promise in Phase 1 DMD Treatment Trial Results - Stock Titan
Keros Therapeutics, Inc. $KROS Shares Sold by Alkeon Capital Management LLC - MarketBeat
Invesco Ltd. Grows Stock Position in Keros Therapeutics, Inc. $KROS - MarketBeat
Can Keros Therapeutics Inc. reach all time highs this yearMarket Risk Summary & Safe Entry Point Identification - beatles.ru
Keros Therapeutics, Inc. $KROS is ADAR1 Capital Management LLC's 8th Largest Position - MarketBeat
PDT Partners LLC Buys New Position in Keros Therapeutics, Inc. $KROS - MarketBeat
What institutional flow reveals about Keros Therapeutics Inc.Portfolio Value Report & Daily Stock Momentum Reports - Newser
What MACD and RSI say about Keros Therapeutics Inc.Weekly Risk Summary & AI Optimized Trading Strategy Guides - Newser
Real time alert setup for Keros Therapeutics Inc. performance2025 Valuation Update & AI Powered Market Trend Analysis - Newser
Keros Therapeutics Inc. stock outlook for YEARWeekly Risk Summary & AI Powered Market Trend Analysis - Newser
Keros Therapeutics, Inc. $KROS Shares Sold by Russell Investments Group Ltd. - MarketBeat
464,895 Shares in Keros Therapeutics, Inc. $KROS Purchased by DRW Securities LLC - MarketBeat
Will Keros Therapeutics Inc. benefit from green energy policiesJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - خودرو بانک
Is Keros Therapeutics Inc. backed by strong institutional buyingDollar Strength & Real-Time Sentiment Analysis - خودرو بانک
Can Keros Therapeutics Inc. lead its sector in growthEarnings Recap Report & Daily Profit Focused Stock Screening - خودرو بانک
What candlestick patterns are forming on Keros Therapeutics Inc.July 2025 Selloffs & Verified Momentum Stock Ideas - Newser
Short interest data insights for Keros Therapeutics Inc.Market Sentiment Report & AI Forecast Swing Trade Picks - Newser
Keros Therapeutics Inc. stock trend forecastCPI Data & Fast Gaining Stock Strategy Reports - Newser
How to build a dashboard for Keros Therapeutics Inc. stock2025 Support & Resistance & Growth Focused Stock Pick Reports - Newser
Can Keros Therapeutics Inc. hit a new high this monthJuly 2025 Outlook & AI Powered Trade Plan Recommendations - Newser
Is this a good reentry point in Keros Therapeutics Inc.Weekly Stock Report & Daily Oversold Bounce Ideas - Newser
Exit strategy if you’re trapped in Keros Therapeutics Inc.Jobs Report & Weekly Consistent Profit Watchlists - Newser
Is Keros Therapeutics Inc. forming a breakout patternWeekly Trade Analysis & Weekly High Return Forecasts - خودرو بانک
103,826 Shares in Keros Therapeutics, Inc. $KROS Acquired by Jump Financial LLC - MarketBeat
Charles Schwab Investment Management Inc. Sells 37,759 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Real time social sentiment graph for Keros Therapeutics Inc.2025 Price Targets & Real-Time Price Movement Reports - Newser
Walleye Capital LLC Sells 47,163 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics Inc. stock chart pattern explained2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - Newser
Intraday pattern recognizer results for Keros Therapeutics Inc.2025 Earnings Surprises & Stepwise Trade Signal Implementation - Newser
Pattern recognition hints at Keros Therapeutics Inc. upside2025 Geopolitical Influence & AI Driven Price Predictions - Newser
Published on: 2025-09-03 23:43:48 - Newser
Analyzing Keros Therapeutics Inc. with risk reward ratio chartsWeekly Trade Recap & Verified Momentum Watchlists - Newser
Is it time to cut losses on Keros Therapeutics Inc.Trade Risk Summary & Long-Term Safe Investment Plans - Newser
Statistical indicators supporting Keros Therapeutics Inc.’s strengthPortfolio Risk Summary & Comprehensive Market Scan Reports - Newser
Applying chart zones and confluence areas to Keros Therapeutics Inc.IPO Watch & Safe Capital Growth Trade Ideas - Newser
Does Keros Therapeutics Inc. qualify in momentum factor screening2025 Risk Factors & Free Fast Entry Momentum Trade Alerts - Newser
Technical signs of recovery in Keros Therapeutics Inc.Portfolio Update Summary & Safe Capital Growth Tips - Newser
How to escape a deep drawdown in Keros Therapeutics Inc.Analyst Upgrade & Weekly Watchlist of Top Performers - Newser
Published on: 2025-09-03 02:58:10 - Newser
Tick level data insight on Keros Therapeutics Inc. volatilityJuly 2025 Outlook & Daily Momentum Trading Reports - Newser
Vanguard Group Inc. Has $26.15 Million Stock Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Leading vs lagging indicators on Keros Therapeutics Inc. performanceJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - Newser
Keros Therapeutics shares rise 1.46% after-hours following the release of DelveInsight's TGFB Inhibitor Pipeline Outlook 2025 report. - AInvest
Keros Therapeutics Inc (KROS) 財務データ
収益
当期純利益
現金流量
EPS
14.24%
0.06%
大文字化:
|
ボリューム (24 時間):